Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Pieter Sonneveld, MD, PhD
Advertisement
Articles by Pieter Sonneveld, MD, PhD
Pieter Sonneveld, MD, PhD, discusses CAR T-cell therapy and bispecific antibodies moving to frontline myeloma care.
Pieter Sonneveld, MD, PhD, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.
Advertisement
Latest Updated Articles
What Stood Out at IMS 2026? 5 Myeloma Experts Weigh InOctober 2nd 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5